Other grades of this product :
| LX-4211 Basic information |
| Product Name: | LX-4211 | | Synonyms: | (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol;CS-1853;LX4211; LX 4211; LX4211; LX 4211;LX-4211;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(Methylthio)tetrahydro-2H-pyran-3,4,5-triol;(5S)-Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-beta-L-xylopyranoside;Sotagliflozin;LX4211/LX-4211 | | CAS: | 1018899-04-1 | | MF: | C21H25ClO5S | | MW: | 424.94 | | EINECS: | | Product Categories: | | Mol File: | 1018899-04-1.mol |
| LX-4211 Chemical Properties |
| Boiling point | 607.9±55.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | pka | 12.87±0.70(Predicted) |
| LX-4211 Usage And Synthesis |
| Uses | Sotagliflozin is used for the treatment of patients with type 1 diabetes mellitus. | | Clinical Use | Two of the current SGLT-2 inhibitors (canagliflozin and LX-4211) have effects on SGLT-1. LX-4211 is a dual SGLT1/2 inhibitor and higher doses of canagliflozin transiently inhibit SGLT-1 in the gut due to high canagliflozin concentrations within the intestinal lumen during the period of drug absorption. | | Synthesis | Sotagliflozin is a dual SGLT-1/SGLT-2 inhibitor which is currently under development by Lexicon Pharmaceuticals (phase III). It follows a similar strategy to ertugliflozin, i.e. aryl addition on an acyclic precursor. The synthesis starts from L-xylose 53, and the aryl moiety (same aryl moiety as for dapagliflozin) is introduced on an amide derivative (morpholine amide 54) via Grignard addition. A subsequent transformation leads to the sotagliflozin (Scheme 10). The overall yield of the synthesis is around 30%.
Sotagliflozin synthesis
|
| LX-4211 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye